ResMed downgraded to Sector Perform RBC Capital Markets downgraded ResMed to Sector Perform from Outperform, citing fiscal 2027 challenges. The price target was lowered to $234 from $276. ResMed faces a slew of challenges in the upcoming fiscal year.
ResMed downgraded to Sector Perform
RBC Capital Markets downgraded ResMed to Sector Perform from Outperform, citing fiscal 2027 challenges.
The price target was lowered to $234 from $276.
ResMed faces a slew of challenges in the upcoming fiscal year.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
